Shemha Health Ltd：人工智能驱动的全方位患者临床智能系统（保加利亚）

20250327

医药健康

PrOPA 360° AI represents a technological leap in AI-driven oncology care, surpassing conventional clinical decision support (CDS) systems by integrating advanced AI algorithms, large-scale evidence-based medicine (EBM) frameworks, and real-time oncology data synthesis. Unlike traditional rule-based CDS tools or general AI-powered health solutions, PrOPA leverages Ambient Patient-Clinical Intelligence (A.P.C.I.), an AI-driven multidisciplinary framework tailored specifically for oncology decision-making.2. Comparative Analysis: Key Differentiators in AI-Powered Oncology Real-Time, AI-Driven Personalized Decision Support: · Unlike IBM Watson for Oncology, which relies on pre-programmed rule-based AI, PrOPA actively processes new clinical data in real-time, generating fully personalized patient pathways in 310 seconds. · Competing platforms such as Flatiron Health use machine learning (ML) models but focus on population-based insights rather than individualized real-time decision support. First AI-Powered Tumor Board Decision-Making System · PrOPA 360° AI integrates a digital Multidisciplinary Tumor Board (MTB), enabling AI-enhanced real-time collaboration among oncologists, radiologists, pathologists, and surgeons. · Competing solutions like IBM Watson and Flatiron Health lack this integration, making PrOPA the first AI-driven oncology decision-support platform to facilitate multidisciplinary treatment planning in real-time. Evidence-Based AI with GRADE Methodology · Unlike generic AI models, PrOPA strictly follows GRADE (Grading of Recommendations Assessment, Development, and Evaluation) methodologies. · This ensures scientific-grade recommendations based on clinical trials, meta-analyses, and real-world oncology guidelines. Multi-Language, Global Adaptability · Competing solutions like Flatiron Health and IBM Watson operate primarily in English-based clinical environments. · PrOPA 360° AI supports multiple languages, ensuring global accessibility and localized adaptation for diverse healthcare systems. Interoperability with Hospital EHRs · Unlike IBM Watson, which faced challenges in EHR integration, PrOPA is fully compatible with HL7 FHIR, SNOMED CT, and ICD-10/11 standards, making it seamlessly integrable into existing oncology workflows.4. Future Innovations & Scalability · AI-Driven Predictive Oncology: PrOPA is currently training deep-learning models to predict cancer progression, enabling early intervention and personalized treatment modifications. · Real-World Data (RWD) & AI-Enhanced Research: Unlike competitors focused solely on CDS, PrOPA will integrate real-world oncology datasets to support clinical trials, drug discovery, and AI-enhanced cancer research. · Global Expansion & Multimodal AI Integration: With ongoing clinical trials in Europe (Portugal, Cyprus, Romania), India and the Middle East (Jordan, Kuwait), PrOPA is on track for global deployment by 2026. 5. Why PrOPA 360° AI could be a Market Leader · First AI-driven oncology system with real-time personalized decision-making: Faster, more accurate, and highly integrative compared to IBM Watson, Flatiron, and OncoLink. · The only AI-powered Multidisciplinary Tumor Board Decision-Support System: Facilitates real-time collaboration between oncologists, radiologists, and pathologists. · Evidence-based AI following GRADE methodologies: Ensuring AI-generated recommendations align with international oncology guidelines. · Regulatory & Hospital Integration Ready: EU MDR Class IIb in progress, GDPR & EHDS compliant, fully compatible with EHRs. Global Scalability: Expanding across Europe, North America, and the Middle East, making PrOPA the most accessible oncology AI solution worldwide.-PrOPA 360° AI represents a fundamental shift in oncology care, combining cutting-edge AI-driven clinical decision support, real-time evidence synthesis, and seamless hospital interoperability. The sustainability and irreplaceability of its technology stem from its unique AI architecture, deep integration with international oncology guidelines, and regulatory-compliant infrastructure. However, like any pioneering innovation, PrOPA must navigate potential risks in technology achievability, reliability, regulatory compliance, intellectual property, market competition, and long-term adoption sustainability.

1. Technology Achievability and Reliability PrOPA 360° AI has already demonstrated its feasibility by successfully undergoing clinical validation and AI model refinement in real-world oncology environments. Unlike traditional rule-based clinical decision systems, which require manual updates and struggle with real-time adaptability, PrOPA leverages Large Language Model (LLMs) with Clinical Retrieval-Augmented Generation (RAG) and AI-Ambient Patient-Clinical Intelligence (A.P.C.I.), ensuring continuous learning from new clinical data. Detected potential risks exist: · Healthcare professionals may be reluctant to trust Gen-AI-generated recommendations without transparent decision-making processes. PrOPA mitigates this by integrating GRADE methodologies, ensuring all AI-driven recommendations are scientifically validated and interpretable. · The AI model requires continuous adaptation to different medical systems, languages, and data structures. To address this, PrOPA is built on a modular, cloud-native infrastructure, allowing it to be tailored for varied healthcare environments without loss of accuracy.
2. Intellectual Property and Competitive Differentiation As AI in healthcare evolves, intellectual property (IP) protection becomes critical in maintaining technological exclusivity. PrOPA 360° AI has established strong IP foundations, securing patents on its AI-Ambient Patient-Clinical Intelligence framework, proprietary evidence-based oncology reasoning models, and biostatistics-driven AI decision-support technology. Our key challenges in IP protection: · While competitors may attempt to develop similar AI-based decision-support systems, PrOPA’s proprietary AI algorithms, clinical validation methodology, and unique integration with multidisciplinary tumor teams (MDTs) create a technological moat that is difficult to replicate. · Unlike many AI systems that require vast patient datasets for training, PrOPA does not rely on direct patient data for model development. Instead, it uses scientific meta-analyses, international guidelines, and synthetic data techniques, reducing risks related to data privacy regulations and third-party data dependency.
3. Application Feasibility and Clinical Integration One of PrOPA’s defining strengths is its seamless interoperability with hospital systems, ensuring real-world application feasibility. Unlike AI tools that operate in isolation, PrOPA integrates directly into oncology workflows, supporting oncologists, radiologists, pathologists, and multidisciplinary cancer teams. Potential barriers include: · The introduction of AI into oncology decision-making requires structured physician education to enhance trust and usability. PrOPA addresses this by partnering with academic institutions, hospital networks, and regulatory bodies to facilitate AI literacy programs. · While PrOPA aligns with EU MDR, GDPR, and EHDS regulations, different regions have varying regulatory landscapes (e.g., FDA in the US, HTA frameworks in Asia). We are working to secure approvals across multiple jurisdictions, ensuring global scalability.
4. Market Competition and Differentiation Risks The healthcare AI market is evolving rapidly, with multiple players including IBM Watson (now discontinued), Flatiron Health, OncoLink, and Teledoc Health, attempting to establish dominance in oncology AI. However, PrOPA 360° AI has several irreplaceable advantages that differentiate it from competitors: · Unlike Flatiron Health, which provides population-level oncology insights, PrOPA delivers patient-specific recommendations in real-time. · First AI-Powered Multidisciplinary Tumor Board (MTD) Platform: No other AI solution currently offers real-time AI-driven tumor board decision-making, making PrOPA a unique, first-mover technology. · Many AI-powered healthcare solutions struggle with compliance and adoption. PrOPA has already aligned with international oncology guidelines, focused to be MDR compliance, and GDPR security frameworks, allowing for faster regulatory approvals and hospital partnerships. · Unlike black-box AI models, PrOPA follows GRADE methodologies, ensuring full transparency and physician trust in clinical decision-making.
5. Policy and Regulatory Risks Healthcare AI operates within strict regulatory environments, which present potential risks such as: · New frameworks like the EU AI Act and FDA’s evolving stance on AI-based medical devices could introduce stricter requirements. PrOPA mitigates this by actively engaging with regulatory bodies to ensure early compliance with future policy changes. · The use of AI in clinical decision support must align with ethical guidelines to prevent biases. PrOPA has integrated bias detection algorithms, AI fairness testing, and human-in-the-loop oversight, ensuring responsible AI deployment.
6. Team and Organizational Stability The sustainability of any deep-tech innovation relies on the strength of its leadership and team. PrOPA is backed by a multidisciplinary team of AI researchers, oncologists, regulatory specialists, and healthcare industry leaders, ensuring that its development remains scientifically rigorous, clinically validated, and market-driven. · Strategic alliances with São João University Hospital, German Cancer Center, and Army Hospital, Cancer Center, Kolkata, India ensure ongoing clinical validation and physician engagement. · Dedicated compliance professionals are ensuring MDR, GDPR, and EHDS alignment, reducing regulatory-related risks. Internal teams continuously audit AI performance and fairness, ensuring sustained accuracy and physician trust.

PrOPA 360° AI has advanced beyond its initial research and development phase and is now in the clinical validation and early commercialization stage. With a Technology Readiness Level (TRL) of 6, the platform has moved from proof of concept and laboratory testing to real-world implementation in clinical settings. It is undergoing retrospective validation trials across multiple oncology centers, demonstrating its capability to support oncologists, tumor boards, and healthcare systems with AI-driven, real-time clinical decision support. The technology is mature enough for pilot industrial deployment, and the groundwork for full-scale market entry and regulatory compliance is actively being laid.

At the technological level, PrOPA 360° AI leverages advanced artificial intelligence, large language model (LLM), retrieval-augmented generation (Clinical RAG) with science-driven algorithm behind to process structured and unstructured clinical data, ensuring personalized, evidence-based cancer treatment recommendations. Unlike static decision-support systems, PrOPA continuously integrates new oncology research, clinical guidelines, and patient data to provide real-time adaptive treatment insights. Its Ambient Patient-Clinical Intelligence (A.P.C.I.) framework enables oncologists to access structured patient insights while facilitating multidisciplinary tumor board (MTB) collaboration. The platform integrates Natural Language Processing (NLP) for clinical data synthesis, HL7 FHIR for interoperability with hospital Electronic Health Records (EHRs), and GDPR-compliant AI for privacy protection.

From an industrialization perspective, PrOPA 360° AI is a cloud-native AI-powered software solution, meaning its deployment does not require physical manufacturing but rather scalable AI model optimization, cloud infrastructure development, and hospital integration capabilities. The supporting resources for industrialization include clinical validation partnerships, regulatory approval processes, financial backing, and technological scalability efforts. Clinical validation is actively underway in leading European and Middle Eastern cancer centers, such as São João University Hospital (Portugal), the German Cancer Center (Cyprus), and the Army Hospital, Cancer Center - Kolkata (India). These institutions are conducting retrospective validation trials on 2,500+ anonymized Electronic Health Records (EHRs) to confirm the accuracy, reliability, and impact of PrOPA’s AI-powered oncology recommendations.

Regulatory compliance is another critical aspect of industrialization, and PrOPA 360° AI is already aligned with GDPR and EHDS data regulations while undergoing EU MDR Class IIb certification to ensure its suitability for clinical deployment in European hospitals. Future expansion into the U.S. market is also being prepared, with FDA regulatory assessments expected to begin in 2026. PrOPA's interoperability with SNOMED CT and HL7 FHIR ensures that the platform can be easily integrated into existing hospital and healthcare systems, making its industrial-scale deployment more seamless.

In terms of the technology life cycle, PrOPA is currently in the early industrialization stage, transitioning from clinical validation to early market adoption. The roadmap for scalability and commercialization follows a phased industrialization process, with pilot deployments in Europe and the Middle East in 2025, followed by broader market expansion across North America and Asia by 2026. As AI in healthcare continues to evolve, PrOPA is positioned as a long-term, adaptable oncology solution that can integrate new research findings, regulatory updates, and clinical AI advancements, ensuring its sustainability in the global oncology market.

Looking ahead, by the end of 2026, PrOPA 360° AI aims to be deployed in over 30 Comprehensive Cancer Centers (CCCs), processing millions of oncology patient cases through AI-powered decision support. With its robust AI capabilities, regulatory preparedness, and industry endorsements, PrOPA is on track to become a leading AI-powered oncology platform, shaping the future of precision cancer care.

知识产权情况： 专利,商标,版权 成果权属： 其他 该技术潜在应用场景及目标客户： PrOPA 360° AI is designed to address critical gaps in oncology care, providing AI-powered clinical decision support, multidisciplinary collaboration, and real-time evidence-based treatment recommendations. Its versatility and scalability allow it to be integrated into various healthcare settings, ensuring widespread applicability and high market demand.

1. Application Scenarios Comprehensive Cancer Centers & Oncology Hospitals: Enhances physician decision-making by providing real-time, evidence-based treatment recommendations. Supports multidisciplinary tumor boards (MTBs) with AI-assisted case analysis, staging, and therapy selection. Improves workflow efficiency, reducing time spent on manual treatment planning by 70%.
2. Telemedicine & Remote Oncology Care Enables virtual oncology consultations, particularly beneficial for rural and underserved regions. Provides AI-driven second opinions to oncologists and general practitioners. Improves access to specialized oncology expertise, helping hospitals in low-resource settings offer high-quality care.
3. Clinical Research & Pharmaceutical R&D Supports AI-assisted HTA assessment and the clinical trial data comparison. Assists in real-world data analysis for oncology drug development. Accelerates drug efficacy studies by providing AI-powered insights into treatment outcomes.
4. Health Insurance & Value-Based Cancer Care Helps insurers and healthcare payers optimize oncology diagnosis and treatment coverage and reimbursement models. Enables cost-effectiveness analysis, reducing unnecessary testing and treatments. Enhances personalized medicine approaches, leading to better patient outcomes at lower costs.
5. Target Customers & Market Demand PrOPA 360° AI is positioned for high adoption across multiple customer segments in the healthcare industry: · Oncology Hospitals & Comprehensive Cancer Centers (CCCs) Primary users: Multidisciplinary cancer care teams. Market demand: Over 168 CCCs in Europe, thousands of oncology hospitals worldwide. Business model: B2B subscriptions, per-patient licensing models for seamless hospital integration. · Private Clinics & Tele-Oncology Providers Primary users: Telemedicine oncologists, general practitioners, regional cancer centers. Market demand: Growing telemedicine adoption, particularly in Europe, the Gulf Region, and North America. Business model: Pay-per-use AI assistance and subscription-based clinical decision support. · Pharmaceutical & Biotech Companies Primary users: Oncology drug developers, R&D and Market Access teams. Market demand: Increasing reliance on AI-assisted clinical trial optimization. Business model: B2B partnerships, AI-powered research collaborations. · Health Insurance & Government Healthcare Agencies Primary users: Public health authorities, insurance companies, policymakers. Market demand: Rising need for value-based cancer care solutions. Business model: Partnerships for AI-powered cost-efficiency analysis and reimbursement modeling.
6. Market Potential & Global Demand · Over 20 million new cancer cases diagnosed annually worldwide, driving demand for efficient oncology decision-support solutions. · The global AI-in-healthcare market is projected to exceed $188 billion by 2030, with oncology being a key application. Governments and hospitals are prioritizing AI-powered workflow automation, increasing adoption of oncology AI solutions like PrOPA. 产品形态： 最终消费产品 产品描述： PrOPA 360° AI is a fully developed AI-powered tele-oncology platform that has successfully transitioned from research and development to clinical validation and early commercialization. Designed to streamline cancer diagnosis, treatment planning, and multidisciplinary collaboration, the platform delivers real-time, evidence-based clinical recommendations with high accuracy and efficiency. · Product Status: MVP launched, undergoing clinical validation in leading cancer centers, and in the regulatory approval process (EU MDR Class IIb, GDPR, EHDS). · Designability & Creativity: PrOPA integrates advanced AI models (LLMs, NLP, Clinical RAG, CV) with oncology clinical workflows, offering a human-centric AI approach that ensures real-world usability, physician acceptance, and seamless EHR integration. · Key Features & Functionalities: o AI-Driven Clinical Decision Support – Generates personalized patient pathways in 310 seconds, saving 70% of physicians’ time. o Multidisciplinary Tumor Board Collaboration – The first AI-powered real-time tumor board assistant, enhancing team-based oncology care. o Telemedicine & Remote Oncology Access – Enables virtual consultations and AI-assisted second opinions, improving global cancer care accessibility. o Real-World Data (RWD) & Clinical Research Integration – Supports AI-driven oncology research, clinical trials, and drug development. · Creativity & Differentiation: o Unlike static AI solutions, PrOPA is dynamic, real-time, and highly personalized. o Only AI solution with integrated multidisciplinary tumor board decision-making. Regulatory-ready, hospital-integrated, and designed for global scalability.

合作方式： 技术联合研发,股权投资合作,成立独资或合资公司,创新技术产品市场开拓,创新技术供应链合作 合作方式描述：

1. Comprehensive Cancer Centers & Leading Hospitals (Clinical Validation & Deployment) · Properties: Tier-1 hospitals, national oncology centers, academic medical institutions. · Field: Oncology, AI-driven medical diagnostics, telemedicine. · Industry Status: National leaders in cancer care, pioneering AI adoption in healthcare.
2. Medical AI & Digital Health Companies (AI Localization & Product Adaptation) · Properties: AI-driven healthcare startups, established health-tech companies, big data firms. · Field: AI-powered clinical decision support, EHR interoperability, cloud-based medical solutions. · Industry Status: Partners for AI model localization, regulatory adaptation, and data integration.
3. Government & Regulatory Authorities (Policy & Market Entry Approvals) · Properties: National health ministries, AI regulatory bodies, medical device certification agencies. · Field: Health policy, AI-driven medical device regulations, clinical research governance. · Industry Status: Facilitators of compliance with China’s NMPA (National Medical Products Administration), India’s CDSCO, and Singapore’s HSA.
4. Pharmaceutical & Biotech Companies (AI-Driven Clinical Trials & Drug Development) · Properties: Oncology drug manufacturers, biotech firms, CROs. · Field: Precision oncology, AI-assisted drug RWE and PROs, personalized medicine. · Industry Status: Collaborative partners for real-world data analysis, AI-assisted clinical trials, and biomarker-based treatment optimization.
5. Insurance & Healthcare Financing Companies (AI-Powered Value-Based Cancer Care) · Properties: Public and private health insurance companies, medical reimbursement regulators. · Field: Health financing, AI-assisted insurance risk assessment, oncology coverage policies. · Industry Status: Stakeholders in AI-driven cost-effectiveness analysis and personalized insurance modeling.

Our Cooperation Business Models & Market Entry Strategies

1. Technology Licensing & Joint Development – Partnering with local AI firms & health-tech startups to localize PrOPA’s AI models, ensuring compliance with China’s NMPA and Asia-Pacific regulatory frameworks.
2. Hospital-Based Clinical Validation & Deployment – Establishing pilot projects in leading oncology hospitals, integrating PrOPA with local EHRs, telemedicine platforms, and cancer treatment workflows.
3. Government & Policy Collaboration – Working with health ministries and AI regulatory bodies to support AI adoption in cancer care, contributing to national healthcare AI policies.
4. Pharma & Biotech Partnerships for AI-Driven Drug Development – Enabling AI-assisted clinical results assessment, biomarker-based treatment pathways, and real-world data (RWD) analysis for precision medicine.
5. AI-Enhanced Health Insurance Partnerships – Implementing AI-powered value-based reimbursement models, optimizing cancer treatment cost-efficiency. Our Cooperation Targets & Expected Outcomes
6. Regulatory Approval & Market Entry – Achieve NMPA (China) approvals for full-scale commercialization.
7. Hospital Integration & Expansion – Deploy PrOPA in leading oncology hospitals across China within 3 years.
8. AI-Driven Cancer Research & Drug Development – Collaborate with top biotech firms and pharma companies to support AI-powered clinical decision-making analyses/PROs, RWE and drug efficacy analysis.
9. Telemedicine & Rural Healthcare Access – Expand AI-driven remote oncology consultations, supporting underserved populations in China. Insurance & Public Health Adoption – Integrate AI-powered risk assessment models for cancer care insurance, optimizing cost-efficiency for public and private healthcare financing. 融资情况及需求： PrOPA 360° AI is at a critical growth phase, transitioning from clinical validation to commercialization. To accelerate market entry, regulatory approvals, and AI-driven oncology expansion, Shemha Health is actively seeking strategic investment and financing partners to support its next milestones.
10. Current Financing Needs · Immediate Capital Raise: €500,000 Pre-Seed Round · Objective: Support clinical validation, regulatory approvals, and early commercialization efforts. · Current Investment & Funding Secured: €150,000 secured from IT corporate investors. €25,000 secured from Angel investor. Over €100,000 in funding commitments from VC.
    · Public Grants & Accelerator Programs: Engaged with EIC Accelerator and Microsoft for Startups, securing additional non-dilutive funding.
11. Growth Investment: €3.5 Million Seed+ / Series A · Objective: Full-scale commercialization across Europe, Middle East, and Asia. · Funding Allocation: Fast-track regulatory approvals EU MDR, NMPA (China), CDSCO (India) and FDA clearance. · Market Expansion: Deploy PrOPA in 30+ Comprehensive Cancer Centers (CCCs) and hospitals globally. · AI Optimization: Enhance multilingual support, deep-learning accuracy, and real-time tumor board AI integration.
12. Market Valuation & Investment Potential · Current Valuation: €6,7 Million (as per pre-seed investor due diligence). · Projected Valuation (Post-Seed+ Round): €25-30 Million based on hospital adoption and regulatory approvals. · Market Opportunity: AI-powered oncology solutions are expected to grow into a $188 billion industry by 2030, positioning PrOPA as a leading AI-driven cancer care platform.
13. Ideal Investment & Strategic Partnerships · Healthcare VCs & Deep-Tech Investors – Early-stage and growth-stage investors in AI, digital health, and MedTech. · Pharmaceutical & Biotech Companies – Collaborations for AI-driven clinical trials, real-world data insights, and precision medicine. · Hospital Networks & Telemedicine Providers – Partnerships for direct market integration and hospital-wide AI adoption. · Health Insurance & Value-Based Care Investors – AI-powered oncology insurance models for cost optimization and cancer risk assessment.
14. Why Invest in PrOPA 360° AI? · First AI-Powered Tumor Board & Clinical Decision Support System – No direct competitor offers real-time AI-driven cancer treatment planning. · Regulatory-Ready AI for Clinical Deployment – MDR Class IIb & FDA compliance in progress. · Massive Market Potential & Global Scaling Opportunities – Partnerships with hospitals in Europe, China, India, and the Middle East Africa, making PrOPA one of the most scalable AI-driven healthcare solutions worldwide. With strategic funding, PrOPA 360° AI is poised to revolutionize oncology care, bringing precision medicine and AI-powered decision support to hospitals and patients worldwide.

1. Background of Technology R&D Cancer is a global health crisis, with over 4.5 million new cases diagnosed annually in the EU alone. Despite advances in treatment, oncology care remains fragmented, with delays in diagnosis, overwhelmed physicians, and gaps in multidisciplinary collaboration. Patients often face long waiting times, inconsistent treatment recommendations, and disparities in access to expert oncology care. In response to these challenges, Shemha Health developed PrOPA 360° AI—a cutting-edge AI-powered tele-oncology platform designed to transform cancer care. By leveraging Artificial Intelligence (AI), Machine Learning (ML), and Natural Language Processing (NLP), PrOPA provides instant, evidence-based treatment recommendations while enhancing collaboration among healthcare professionals. With its ability to analyze vast amounts of clinical data, optimize workflows, and support multidisciplinary teams (MDTs) in real-time, PrOPA is not just an innovation, it is a paradigm shift in oncology care.
2. The Technology Behind PrOPA 360° AI PrOPA 360° AI is a cloud-based AI decision-support system that seamlessly integrates into hospital workflows, providing real-time oncology insights for doctors, tumor boards, and patients. The system utilizes Ambient Patient-Clinical Intelligence (A.P.C.I.), a human-centric AI framework that synthesizes structured and unstructured data to enhance cancer care. Key Technology Features: ✔ AI-Driven Clinical Decision Support – Analyzes patient data to generate treatment recommendations in seconds. ✔ Multidisciplinary Collaboration – Enables real-time interaction between oncologists, radiologists, and pathologists. ✔ Natural Language Processing (NLP) & Large Language Models (LLMs) – Extracts insights from EHRs, medical literature, and guidelines. ✔ HL7 FHIR & SNOMED CT Integration – Ensures interoperability with electronic health records and telemedicine platforms. ✔ GRADE Methodology – Aligns treatment decisions with all meta-analyses and scientific papers worldwide, referring international oncology guidelines (such as ASCO, ESMO, NCCN). ✔ Predictive Analytics for Personalized Oncology – Uses ML models to forecast patient outcomes and optimize treatment pathways. The AI-driven system generates personalized patient pathways in 310 seconds, offers clinical recommendations in 200 seconds, and saves over 70% of oncologists' time while ensuring 95% diagnostic accuracy.
3. Solving Critical Challenges in Oncology PrOPA 360° AI was designed to address key bottlenecks in cancer care: ✔ Delays in Diagnosis & Treatment – AI accelerates oncology decision-making, reducing the time from diagnosis to treatment from weeks to minutes. ✔ Overburdened Physicians & Lack of Standardization – Automates clinical workflows, providing real-time, guideline-based recommendations that ease cognitive overload. ✔ Limited Access to Specialized Care – PrOPA functions as a virtual expert oncologist, making top-tier cancer care accessible to patients regardless of location. ✔ Fragmented Patient Data – Aggregates structured and unstructured data from biopsy results, radiology scans, genomics, and patient history into a unified oncology dashboard. ✔ Rising Healthcare Costs – Reduces diagnostic and treatment inefficiencies, saving up to 15% in healthcare expenses per patient.
4. Stages of Development & Global Validation ✔ MVP Launch (Q4 2023) – Successfully tested with 80+ clinical specialists in 24 oncology fields. ✔ Clinical Validation in Progress (2024-2025) – Real-world deployment in leading oncology centers, including: · São João University Hospital (Portugal) · German Cancer Center (Cyprus) · Army Hospital, Cancer Center - Kolkata (India); etc. ✔ Regulatory Readiness – EU MDR Class IIb certification in progress, GDPR and EHDS compliance ensured, targeting FDA clearance by 2026. ✔ Expansion Roadmap – Deploying across Europe, the Gulf Region (Jordan, Kuwait), India, and North America (MD Anderson, USA, Canada).
5. Industry Recognition & Awards · Forbes Startup of the Year 2024 (Bulgaria) · HITLAB US Breakthrough Alliance Challenge Finalist · Global Bio India Finalist · HICOOL Beijing Finalist · MedTech World 2024 AI in Healthcare Nominee PrOPA 360° AI has gained endorsements from major organizations such as the European Cancer Organization (ECO), the Organization of European Cancer Institutes (OECI), and All.Can International, reinforcing its credibility and potential for global impact.

Visualization: AI-Powered Oncology Workflow

Visualization: AI-Powered Oncology Decision-Support System

A Future-Ready Solution for Global Cancer Care As cancer cases continue to rise, AI-driven oncology solutions like PrOPA 360° AI are essential to bridge healthcare gaps, enhance clinical decision-making, and improve patient outcomes.

With its proven impact, global partnerships, and commitment to AI-driven precision medicine, PrOPA 360° AI is poised to set a new standard in oncology care worldwide.。